The most frequently asked comorbidity question after each cluster of hantavirus pulmonary syndrome (HPS) reaches international news is whether people living with HIV (PLWH) face a higher risk. The 2026 MV Hondius cluster has been no exception. The published evidence is meaningfully thinner and more nuanced than the public assumption, and the operational message is more useful than a simple binary. This guide collects what the literature actually says, where the conservative interpretation is defensible, and what PLWH can reasonably do if they live in or travel into Andes virus or Sin Nombre virus endemic regions.
What the published HPS literature shows
The largest published cohorts of HPS — the Argentine Patagonia cohort, the Chilean Servicio de Salud Magallanes ECMO series, and the US Sin Nombre cohort coordinated through the CDC HPS Registry — have together accumulated fewer than two thousand cases over the past three decades. Among those datasets, the predictors that have consistently emerged as independent risks for fatal outcome are older age, male sex, smoking history, and delayed clinical presentation. HIV status is not in the canonical predictor list.
That null result is partly real and partly statistical. HPS is rare. HIV-positive HPS patients are rarer still. The cohorts have not had the power to detect a moderate independent effect from a comorbidity that is present in only a small subset of patients, particularly in geographies where the HIV prevalence in the general population is itself low.
Why a conservative interpretation is still defensible
A conservative interpretation that treats advanced HIV as a potential risk factor for severe HPS is reasonable on biological grounds. HPS pathology is driven in part by an exuberant cytokine response from infected pulmonary capillary endothelium. Impaired cellular and humoral immunity in the early viraemic phase could plausibly produce higher peak viraemia and a steeper capillary leak in the cardiopulmonary phase that follows.
Supportive care during the acute phase is largely supportive — oxygen, intubation if needed, ECMO in the highest-acuity cases. Patients entering that phase with diminished reserve from advanced HIV, an untreated opportunistic infection, or active immune suppression are starting the most dangerous days of the illness from a worse physiological baseline. None of that constitutes a hard mechanistic argument, but it is coherent enough to be biologically plausible and to justify caution in the subset of PLWH with low CD4 counts or detectable viraemia.
Where controlled HIV sits on the risk map
For PLWH on stable antiretroviral therapy with a suppressed viral load and a CD4 count above 350 cells per microlitre, the published epidemiology does not support treating HIV as a meaningful independent risk factor for severe HPS. The practical risk equation for a PLWH traveller with well-controlled HIV is dominated by exposure profile, not host immune status. Travel to a major European or North American city carries effectively no hantavirus risk. Rural travel into Andes virus endemic regions of Argentina and Chile, or Sin Nombre virus endemic regions of the US Four Corners and the Pacific Northwest, introduces the same low background risk as for the general population.
For PLWH with low CD4 counts, detectable viraemia, or an active opportunistic infection, the conservative interpretation supports a higher level of awareness, a lower threshold for medical evaluation, and a coordinated risk-reduction plan with the treating HIV clinician before any travel into endemic regions.
Practical risk-reduction in endemic regions
For PLWH living in or travelling through hantavirus endemic regions, the practical risk-reduction list is the same as for the general population, applied with a slightly lower threshold for caution:
- Avoid cabins, outbuildings, or storage spaces that have been unoccupied for prolonged periods without ventilation.
- Never sweep dry in rodent-affected areas. Wet-disinfect with a 1:10 dilution of household bleach and allow at least five minutes of contact time before any wiping.
- Wear an N95 respirator, sealed goggles, and nitrile gloves if there is no alternative to cleaning a rodent-affected space.
- Avoid camping or sleeping directly on the ground in areas with high rodent density.
- Coordinate with the treating HIV clinician on what symptoms should trigger a same-day evaluation.
- Maintain antiretroviral therapy continuity throughout any trip; do not allow travel logistics to interrupt ART dosing.
When to seek care
For any PLWH who develops fever, severe muscle aches, and shortness of breath within eight weeks of potential rodent exposure, the right action is a same-day medical evaluation with explicit declaration of HIV status, current CD4 count and antiretroviral regimen, and the exposure history. The seven-day window after symptom onset is the critical decision point: HPS patients hospitalised with supportive care during the prodromal phase or at the start of the cardiopulmonary phase have meaningfully better outcomes than those who present late. For PLWH in particular, the early-presentation rule is the single highest-yield intervention.
What this means in practice
Hantavirus is a low-probability but high-consequence infection. HIV status is one variable in a calculation that remains dominated by exposure profile and presentation timing. The published evidence does not support routine travel restrictions or behavioural exclusions for the PLWH community, but it does support a higher level of awareness, an explicit risk-reduction plan, and a low threshold for seeking care — particularly for PLWH with low CD4 counts or detectable viraemia. For most PLWH on stable ART with a suppressed viral load, the practical assessment is the same as for the general public: the risk to anyone not in close prolonged contact with a confirmed Andes virus case is essentially zero outside endemic rural settings, and the risk-reduction protocol for endemic-region travel is the same protocol that protects the general public.